Gilead's remdesivir endorsed as first COVID-19 treatment in Europe

The European healthcare regulator has recommended the conditional approval of Gilead Sciences Inc's antiviral treatment, remdesivir, for use in COVID-19 patients, making it the first treatment to be on track to be green-lit in the continent.

The price of the drug in the region is not yet known. In the United States, it could be priced up to $5,080 per course, while Indian generic drugmakers will sell the treatment between 5,000 rupees to 6,000 rupees . The EU's conditional marketing authorization allows a treatment to be sold for a year in the 27-nation trading bloc before all necessary data on its efficacy and side-effects are available. Gilead has to submit final data by December.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

De Lima: Gov’t must be transparent on how it spends funds for COVID-19 responseMANILA, Philippines — Saying that the public is still “left in the dark” as to how the government is spending funds in response to the coronavirus disease (COVID-19), Senator Leila De Lima on khallareINQ Bakit ba palagi to sa balita? Nakakulong na to ah!
Source: inquirerdotnet - 🏆 3. / 86 Read more »